Dentsply Sirona Appoints Simon Campion as Chief Government Officer

Dentsply Sirona at the moment introduced that Simon Campion has been appointed President and Chief Government Officer and can be part of the Firm’s Board of Administrators (“Board”), efficient September 12, 2022. He succeeds John Groetelaars, who has served as Interim Chief Government Officer since April 2022. Mr. Groetelaars will proceed to serve on the Board. 

Mr. Campion joins Dentsply Sirona from Becton, Dickinson and Firm (“BD”), the place he most lately served as Government Vice President and President of the Medical phase and previous to that served as President of the Interventional phase following BD’s acquisition of C. R. Bard. He beforehand held a number of management roles throughout the C. R. Bard group, together with main the Surgical procedure enterprise unit.

With the hiring of Mr. Campion, the Board has requested a full assessment of the Firm’s enterprise and operations together with aggressive positioning and portfolio, margin enhancement alternatives, and capital construction.

Eric Okay. Brandt, Chairman of the Dentsply Sirona Board, stated, “Simon’s appointment follows a complete search course of to establish the proper chief to assist the Firm ship on its strategic and monetary objectives. Simon is a high-integrity, transformational chief with a report of world-class operational experience and sustainable progress.  In his 25 years within the medical machine {industry}, Simon has led international enterprise items, pushed industrial execution, and developed and executed methods to increase innovation and generate income progress at scale. Throughout his tenure at BD, Simon delivered above-market annualized income progress, accelerated the segments’ M&A exercise, and expanded the natural innovation agenda. We consider Simon’s values and management, can be extremely impactful in transferring the Firm ahead notably because the Firm prepares to finish the continued Audit Committee assessment, enhance operational rigor, and drive accountability.”

Mr. Campion stated, “It’s an honor to hitch Dentsply Sirona and have the chance to steer this nice staff. Throughout my profession, I’ve developed a transparent understanding of what it takes for a worldwide healthcare firm to succeed, and I’m assured that with its robust basis of industry-leading merchandise and patient-driven innovation, Dentsply Sirona is well-positioned to capitalize in the marketplace alternatives forward and ship long-term progress and worth creation.”

Mr. Brandt continued, “The Board is most grateful to the staff of Dentsply Sirona for his or her endurance, resiliency, and dedication to our suppliers and sufferers throughout this time of uncertainty because the Firm prepares for completion of the continued Audit Committee assessment. Moreover, the Board thanks John Groetelaars for his service as Interim Chief Government Officer. Throughout his tenure, John put in place administration techniques which might be key to focusing and advancing the Firm’s high priorities and set an exemplary normal of integrity and accountability. We stay up for persevering with to profit from his experience on the Board.”

Mr. Groetelaars stated, “It has been a privilege to function Dentsply Sirona’s Interim CEO. Over the past a number of months, I’ve gained deep perception into Dentsply Sirona’s enterprise, operations, and alternatives. Dentsply Sirona has a stable technique in place, and I’m keen to use the views I’ve gained as I proceed to help the Firm’s progress from the Board.”

About Simon Campion

Simon Campion beforehand served as Government Vice President & President of the Interventional and Medical segments at BD (Becton, Dickinson and Firm). When BD acquired C. R. Bard in 2017, he initially led the combination of the BD & Bard Surgical procedure companies right into a single enterprise unit and upon taking up the position of Government Vice President & President of Interventional, a $4.2 billion phase in 2021, led the broader phase by means of integration, and oversaw the worldwide strategic, monetary and innovation efficiency of the phase. Mr. Campion’s management generated income progress at scale by means of growth of the phase’s natural innovation agenda and acceleration of its M&A aims. Previous to BD’s acquisition of C. R. Bard, Mr. Campion held a number of management roles throughout the C. R. Bard group within the U.S. and Internationally, together with President of the Surgical procedure enterprise unit. Beforehand he held advertising and R&D roles at Prepare dinner Medical and Boston Scientific.

Mr. Campion earned a Bachelor of Engineering and Ph.D. in Mechanical Engineering from the College of Limerick, Eire and an MBA from the Open College within the UK.

ABOUT DENTSPLY SIRONA                                                                                   

Dentsply Sirona is the world’s largest producer {of professional} dental merchandise and applied sciences, with over a century of innovation and repair to the dental {industry} and sufferers worldwide. Dentsply Sirona develops, manufactures, and markets a complete resolution providing, together with dental and oral well being merchandise in addition to different consumable medical units beneath a powerful portfolio of world class manufacturers. Dentsply Sirona’s merchandise present revolutionary, high-quality and efficient options to advance affected person care and ship higher and safer dental care. Dentsply Sirona’s headquarters are situated in Charlotte, North Carolina. The corporate’s shares are listed in the US on NASDAQ beneath the image XRAY. Go to www.dentsplysirona.com for extra details about Dentsply Sirona and its merchandise.


This info and any attachment thereto incorporates “forward-looking statements” throughout the which means of the protected harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Such statements are usually not ensures of future efficiency. These forward-looking statements replicate views and assumptions concerning expectations and projections about future occasions and are based mostly on at present accessible info or info accessible on the date of any doc included by reference. You possibly can typically establish these forward-looking statements by way of phrases resembling “could,” “may,” “estimate,” “will,” “consider,” “anticipate,” “assume,” “intend,” “anticipate,” “mission,” “plan,” “goal,” “forecast”, and comparable phrases and expressions. Nonetheless, these phrases are usually not the unique technique of figuring out such statements. As well as, any statements that confer with expectations, projections or different characterizations of future occasions or circumstances are forward-looking statements and should embody statements referring to future revenues, bills, margins, profitability, internet revenue/(loss), earnings per share and different measures of outcomes of operations and the prospects of future progress of our enterprise. These forward-looking statements are inherently topic to uncertainties, dangers and modifications in circumstances which might be troublesome to foretell. For a dialogue of such dangers, uncertainties and different issues that might trigger precise outcomes to vary materially, together with dangers referring to, amongst different elements, the marketplace for dental services, pricing, future gross sales quantity of the Firm’s merchandise, the potential for altering financial, market and aggressive circumstances, dependence on merchandise, dependence on key personnel, technological developments, intense competitors, market uncertainties, dependence on distributors, means to handle progress, dependence on key suppliers, dependence on key members of administration, authorities regulation, our means to combine the companies of Dentsply Sirona, acquisitions and affiliations, readers are urged to rigorously assessment and think about varied disclosures made by the Firm and Dentsply Sirona of their public filings, together with of their Annual Experiences on Type 10-Okay and of their experiences on Types 10-Q and 8-Okay filed with the Securities and Trade Fee.

Readers are cautioned to not place undue reliance on such statements, which communicate solely as of the date hereof. Besides as required by regulation, the Firm doesn’t assume any obligation to replace any forward-looking statements contained on this doc or the attachments to replicate new info or future occasions or developments after the date any such assertion is made.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *